CitrISO in transfusion medicine & therapy


The advantages of CitrISO anticoagulants on the basis of tri-arginine citrate compared to tri-sodium citrate or citric acid, respectively, are perfectly obvious:

CitrISO anticoagulant on the basis of tri-arginine citrate is a metabolizable substance without considerable buffer capacity at pH 7.4 ± 0.4 and without effect on the patients metabolism.

Although when treated with conventional citric acid the sodium burden of the patient is lower compared to the treatment with tri-sodium citrate, the consequence is a negative, but reversible, BE (base excess).

When treated with tri-sodium citrate the greater, alkalizing influence on the BEpot (potential base excess) of the patient as well as the significant sodium burden has to be taken into account.

An isotonic, isokalemic, twofold isohydric solution (BE = 0, Bepot = 0) is manufacturable only with CitrISO not with tri-sodium citrate / citric acid.

CitrISO example

For in-vivo application (e.g. CRRT) a solution composed of the following is useful:

24.0 mmol/l sodium hydrogen carbonate
1.5 mmol/l tripotassium citrate
100.0 mmol/l tri-arginine citrate

This isotonic solution with a total citrate concentration of 100.0 mmol/l has an osmolality of 284 mosmol/kg H2O and a pH (37 °C) of 7.12. The solution is isokalemic (potassium 4.5 mmol/l) and twofold isohydric (BE = 0 mmol/l, BEpot = 0 mmol/l).

Sources of supply and scientific argumentation

The raw material tri-arginine citrate, stock solutions for further processing, custom-made specifications and solutions ready to use (IVD) are available at
Bioanalytic GmbH (,

Scientific arguments for CitrISO can be found on the information portal Physioklin ( > PhysioHäm).

Inquiries about cooperation, patent and licence please send to